Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 8/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433427 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL9656236 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL3467780 | 0.82 | SMN1; SMN2 (0.47) | ESR1SMN1; SMN2PPARAPPARG | |
| SCHEMBL4820511 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL5405854 | 0.76 | SMN1; SMN2 (0.60) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL3468498 | 0.75 | ESR1 (0.56) | ESR1ESR2PGRCHRM2ADORA3 | |
| SCHEMBL2231218 | 0.75 | SMN1; SMN2 (0.63) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL2561889 | 0.73 | PPARG (0.68) | SMN1; SMN2PPARAPPARGPOLB | |
| Methane SCHEMBL27838357 | 0.73 | SMN1; SMN2 (0.61) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL3468092 | 0.73 | CA2 (0.59) | ESR1ESR2PGRCHRM2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799828-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | GLAXOSMITHKLINE LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7569601-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213348-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885SMN1; SMN2 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.